Jazz Pharmaceuticals Highlights Upcoming Investor Engagements
Dublin - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced its participation in several key investor events aimed at providing insights into their ongoing initiatives and developments.
Investor Webcast for HERIZON-GEA-01 Trial
The company will host an informative investor webcast focusing on the results from the Phase 3 zanidatamab HERIZON-GEA-01 trial. This event is scheduled for Friday, January 9, 2026, at 6:30 a.m. PT / 3:30 p.m. GMT. The webcast will feature commentary from senior leadership at Jazz Pharmaceuticals along with insights from Dr. Geoffrey Ku, a specialist at Memorial Sloan Kettering Cancer Center.
Webcast Following ASCO GI Presentation
This event is significant as it follows an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) happening a day earlier, on January 8, 2026. Attendees can expect to gain a deeper understanding of the trial's implications for treatment options.
44th Annual J.P. Morgan Healthcare Conference
Following the webcast, Jazz Pharmaceuticals will be participating in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. During this important event, Renee Gala, the company's president and CEO, will present an overview of the company's strategic direction and recent business updates at 11:15 a.m. PST / 7:15 p.m. GMT.
Accessing Live Presentations
Both presentations will be accessible through the Investors section of the Jazz Pharmaceuticals website, allowing stakeholders to connect virtually. A recording of the webcasts will be available on the site for 30 days post-event.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to innovating and transforming the lives of patients and their families. The company's mission is to develop potentially life-changing therapies for serious diseases, especially where options are limited. They maintain a diverse portfolio that includes leading treatments for sleep disorders, epilepsy, and a growing range of cancer therapies.
Commitment to Patients and Innovation
Headquartered in Dublin, Ireland, Jazz Pharmaceuticals operates with research and development facilities, manufacturing sites, and dedicated employees across multiple countries. This robust international presence underscores their commitment to serving patients globally. Their patient-focused and science-driven approach fuels significant advancements in research and the development of innovative therapeutics in oncology and neuroscience.
Investor and Media Contacts
Investors:
Jack Spinks
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
Ireland, +353 1 634 3211
U.S., +1 650 496 2717
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
Ireland, +353 1 637 2141
U.S., +1 215 867 4948
Frequently Asked Questions
What events will Jazz Pharmaceuticals be participating in?
Jazz Pharmaceuticals will take part in the HERIZON-GEA-01 investor webcast and the 44th Annual J.P. Morgan Healthcare Conference.
When is the HERIZON-GEA-01 investor webcast scheduled?
The webcast is set for January 9, 2026, at 6:30 a.m. PT / 3:30 p.m. GMT.
Who will present at the J.P. Morgan Healthcare Conference?
Renee Gala, the president and CEO of Jazz Pharmaceuticals, will present at the conference.
How can I access the webcasts?
The webcasts will be available on the Investors section of the Jazz Pharmaceuticals website, with replays for 30 days after the events.
What is the mission of Jazz Pharmaceuticals?
The mission is to innovate and transform the lives of patients by developing potentially life-changing therapies for serious diseases.
